disease to dialysis in CRF patients, in contrast with the powerful influence of proteinuria, baseline creatinBackground.Dyslipidaemia is common in patients with chronic renal failure (CRF ), and there is increasing ine clearance and nephropathy type in predicting this progression. evidence to support the role of dyslipidaemia as a contributing factor in the progression of chronic renal Key words: chronic renal failure; creatinine clearance; disease. However, few prospective studies have been fibrinogen; homocyst(e)ine; lipids; lipoprotein(a) carried out which address the possible relationship between dyslipidaemia and the rate of progression of renal disease in patients with renal failure. . A number of experimental investi-CRF decline to dialysis, including lipid abnormalities gations have provided relevant evidence that lipids and baseline creatinine clearance were determined at may contribute to progressive renal damage [3], and the start of the follow-up period.
Methods. Between January 1985 and December 1997, Introduction
we prospectively assessed the risk of CRF progression to dialysis in a cohort of 138 patients. Forty CRF Hyperlipidaemia is common in patients with renal patients reached end-stage renal disease ( ESRD) and failure. In addition, atherogenic changes in lipoprotein had to start supportive therapy during the follow-up composition occur in most of these patients [1] . It has period [group ESRD(+)]. The remaining 98 CRF long been hypothesized that lipoproteins play a role in patients served as controls [group ESRD(−)]. Potential renal injury similar to their putative involvement in clinical and laboratory risk factors for more rapid atherosclerosis [2] . A number of experimental investi-CRF decline to dialysis, including lipid abnormalities gations have provided relevant evidence that lipids and baseline creatinine clearance were determined at may contribute to progressive renal damage [3] , and the start of the follow-up period.
several observational studies in humans have also Results. Several significant differences were found in supported this latter role [4] [5] [6] [7] [8] [9] [10] [11] . However, there are univariate analysis between the two groups of CRF, only a few prospective studies that have addressed the ESRD(+) and ESRD(−), namely a shorter follow-up possible relationship between dyslipidaemia observed period, a lower level of baseline creatinine clearance, in patients with renal failure and the rate of progression a faster rate of creatinine clearance decline, a higher in kidney disease [12, 13] . Therefore, additional prolevel of serum triglycerides, fibrinogen, total homospective studies are warranted. cyst(e)ine and proteinuria, and a lower level of serum
In our nephrology division, we prospectively deterhigh-density lipoprotein in the ESRD(+) group than mined clinical and laboratory parameters relevant to in the ESRD(−) group. However, by multivariate Cox atherogenesis in a cohort of pre-dialysis chronic renal analysis proteinuria [relative risk (95% confidence failure (CRF ) patients, and evaluated the incidence interval ) 1.32 (1.16-1.50) for each g/day P=0.001], and risk factors of cardiovascular events over a 10-year baseline creatinine clearance [0.53 (0.40-0.70) for each period [14] . In this paper we extend this follow-up 10 ml/min, P=0.001] and chronic interstitial nephritis period to 31 December 1997. Data from our study and hypertensive nephrosclerosis [0.38 (0. 17-0.84) provide an opportunity to examine prospectively the for presence, P=0.005] were the only significant risk role of dyslipidaemia, as well as of other factors, as factors for CRF progression to dialysis. Hyperpredictors of rapid progression towards end-stage renal triglyceridaemia and male gender were selected in the disease ( ESRD). final model, but were of borderline significance. Conclusions. These results suggest a limited role for dyslipidaemia in the progression of chronic renal Patients and methods
Correspondence and offprint requests to: Ziad A. Massy MD, by a creatinine clearance (Ccr) of 20-70 ml/min, were referred (HDL) cholesterol, apolipoprotein (apo) A-I, apo B, lipoprotein (a) [Lp(a)], fibrinogen and total homocyst(e)ine (Hcy) to our nephrology division. Of these, 147 (99 male, 48 female), had a regular follow-up at our division from baseline levels were determined according to previously described methods [18, 19] . Clinical and laboratory parameters taken Ccr until the start of haemodialysis (HD), or until the end of the follow-up period, and gave their informed consent to into account for correlation analysis were the baseline values at the start of the follow-up. participate in a study of risk factors of atherosclerosis. The recruitment of patients started in January 1985 and terminResults have been expressed as mean±SD, except for serum Lp(a) and proteinuria which have been also expressed ated in April 1994. The remaining 76 patients who lived outside the Paris area, and were usually followed by their as median values. Differences between groups were tested using Student's t-test, analysis of variance (ANOVA) and nephrologists, were referred to our nephrology division for consultations when needed. By consequence, they were not Chi-squared test. The Spearman-Pearson test was used to evaluate the relationship between numeric variables. Possible able to participate in such regular follow up and were excluded. However, age, sex and primary renal disease were risk factors for ESRD (presence or absence of ESRD, i.e. renal death, during the follow-up period ) were examined not significantly different between the patients who participated in the present study and those who did not. Nine of the using univariate Cox proportional hazard analysis. Since the increase of relative risk throughout the four quartiles of age 147 patients who participated in the present study were on lipid-lowering therapy and were also excluded. Thus, only was not fairly consistent, age was encoded into two classes according to the median from the sample. Renal diagnosis 138 patients were included in the current evaluation. All were ambulatory and managed as outpatients. Among them, was entered as two binary covariates for each group (present or not), and evaluated first by nested Cox proportional 40 patients reached ESRD and had to start supportive therapy during the follow-up period [group ESRD(+)]. The hazard analysis. Covariates that tended to correlate with endpoints on univariate analysis (P<0.15) were also examdecision to start dialysis was based on Ccr values between 5-8 ml/min or on the presence of severe clinical manifesta-ined using multivariate Cox analysis. Interaction between variables was tested by using nested Cox proportional hazard tion. The remaining 98 CRF patients had not yet reached ESRD and served as controls [group ESRD(−)]. Among analysis. Since we did not have a comparable baseline Ccr value within the ESRD(−) group for each ESRD(+) patient, them six patients died and six did not complete the followup period.
we carried out the multivariate Cox analysis by adjusting for baseline Ccr. When necessary, differences between groups Primary renal disease was chronic glomerulonephritis [30 and 11% of patients, for ESRD(+) and ESRD(−) groups, were tested using an adjusted survival curve obtained from the multivariate Cox analysis. Final results of multivariate respectively], chronic interstitial nephritis (25 and 41%), hypertensive nephrosclerosis (23 and 31%), polycystic kidney Cox analysis were considered significant for P<0.05. Since only two-thirds of patients had plasma Hcy determinations, disease (20 and 14%) and diabetic nephropathy (2 and 3%). We classified renal diagnosis into three categories according we did not include plasma Hcy in the final Cox proportional hazard models. Statistical comparisons were performed using their potential rate of Ccr decline over time: glomerular disease including diabetic nephropathy (CGN ), polycystic SAS statistical software (SAS Institute Inc., Cary, NC, USA). kidney disease (PKD) and chronic interstitial nephritis or hypertensive nephrosclerosis (CPN+HTN ).
Each patient had at least two visits per year, or at more Results frequent intervals according to the degree of CRF, with assessment of blood pressure, antihypertensive medication The characteristics of the patients at baseline are given [i.e furosemide, beta-blockers, calcium-channel blockers and in Table 1 according to aetiology groups. Patients with angiotensin-converting enzyme (ACE) inhibitors], body CGN or PKD were younger than those with CPN and weight and serum creatinine at each visit. The majority of patients treated with ACE inhibitors had this treatment at HTN. Daily protein intake, as well as body mass index the start of follow-up (>90%). Cardiovascular events consid-were similar in the three groups. The rate of Ccr ered were myocardial infarction, evidence of coronary artery decline was markedly influenced by the type of nephrostenosis on coronary angiography or coronary revascularis-pathy. Thus, it was significantly more rapid in the ation procedure. Cerebrovascular disease considered was CGN and PKD groups than in the CPN+HTN group. ischaemic stroke. Peripheral arterial disease (subocclusive or Proteinuria was strikingly lower in the PKD group occlusive artery disease and/or aneurysm of the abdominal than in the CGN group. The use of ACE inhibitors aorta) was not taken into account because the time of onset was more frequent in CGN and PKD patients than in could not be determined [14] . Ccr was estimated for each CPN+HTN patients. There were more patients who subject from serum creatinine concentration using the Gault reached ESRD in the CGN and PKD groups than in and Cockroft formula, which takes into account age, body the CPN+HTN group. weight and gender, and which has been shown to closely reflect glomerular filtration rate, as measured by inulin Tables 2 and 3 show that among the clinical and clearance and technetium-dietlylene triamine pentacetic acid laboratory parameters assessed, several significant (Tc-DTPA) in subjects with impaired renal function and differences were found between the two groups of renal transplant recipients [15] . Assuming that the rate of CRF, respectively ESRD(+) and ESRD(−), namely Ccr decline in a group of CRF patients is approximately a shorter follow-up period, a lower level of baseline linear [16 ] , we calculated Ccr decline as follows: (Ccr at the Ccr, a faster rate of Ccr decline, a higher level of beginning of follow-up-Ccr at the end of follow-up) serum triglycerides, fibrinogen, total Hcy, and pro-(ml/min)/duration of follow-up period (years). It should be teinuria, and a lower level of serum HDL in the noted that there was no significant change of body weight ESRD(+) group. A more frequent use of antihyperthroughout the follow-up period. Protein intake was calcutensive medication in the ESRD(+) group than in the lated using the formula of Maroni et al [17] . Fasting fresh serum triglycerides, total cholesterol, high-density lipoprotein ESRD(−) group was of borderline significance. In Table 1 contrast, there was no significant difference in the levels of systolic blood pressure, diastolic blood pressure, cigarette consumption, serum total cholesterol or serum apo B. Multivariate Cox analysis identified proteinuria, baseline Ccr and the absence of CPN+HTN, as significant risk factors for developing ESRD ( Table 4) . Hypertriglyceridaemia and male gender were selected in the final model but were of borderline significance ( Table 4) . Systolic blood pressure, cigarette smoking, HDL cholesterol, fibrinogen, protein intake and antihypertensive medication were not predictive of ESRD in CRF patients by multivariate Cox analysis, although adjusted survival-curve obtained from a Cox proportional hazard analysis shows that patients with baseline for each 10 ml/min P=0.001), the absence of triglycerides levels above 1.45 mM (median levels of CPN+HTN (0.29 for presence, P=0.002), gender the whole group; Figure 1) , as well as patients with (2.43 for presence of male, P=0.006) and triglycerides PKD+GNC (Figure 2) It should be noted that proteinuria was found to be positively correlated with systolic blood pressure (r= Table 4 cholesterol, fibrinogen, protein intake and antihypertensive medication.
Discussion
Our prospective, case-control study in patients with moderate CRF shows that a limited association exists between dyslipidaemia and the rate of progression of CRF to dialysis, in contrast with the prominent value of proteinuria, renal function and renal diagnosis in predicting this progression. In addition, it underlines the lack of apparent influence of treated blood pressure, fibrinogen, cigarette smoking and protein intake in the rate of progression of CRF to dialysis in such patients.
Several observational studies in patients have supported the role of lipids as contributors to progressive Modification of Diet in Renal Disease (MDRD) Study, study. Others have also failed to demonstrate such influence [22, 25, 26 ] . However, the MDRD study it was demonstrated that low HDL cholesterol concentrations is one of six co-variants related to the sub-recently showed a slower rate of renal function decline in patients whose blood pressure values were reduced sequent rate of decline in the glomerular filtration rate [12] . In another prospective study, the decline of renal to below the recommended normal values during the period of follow-up, especially in those with higher function over 3 years was significantly associated with baseline concentrations of cholesterol, LDL cholesterol baseline proteinuria [28] . Our patients were all on antihypertensive medication, but were not submitted and apo B, but not with that of triglycerides [13] . In the present study, we could not demonstrate a signific-to a policy of stringent blood pressure control.
Therefore, we cannot exclude that a more aggressive ant role for dyslipidaemia in the rate of progression of CRF to dialysis, and only a weak association was blood pressure control would have exerted a better protective effect. observed between triglycerides and this progression. Several differences between our study and that of As in all epidemiological studies, the present observations should be interpreted with caution. Although Samuelsson and colleagues [13] may explain the observed discrepancy, including a different population, we used multivariate statistical analysis, it is difficult to eliminate the possibility of confounding between use of a different end-point (renal death in our study vs decrease in glomerular filtration rate in the other variables in discerning cause and effect relationships.
In addition, we did not examine putative risk factors study), use of a different multivariate analysis method (Cox proportional hazard analysis vs multiple linear for the progression of CRF not leading to dialysis, and all putative risk factors for the progression of regression, respectively) and a different method of determinating renal function (Gault and Cockcroft CRF to dialysis. Nevertheless, the results of our analysis suggest that baseline proteinuria, renal function formula vs 51Cr-EDTA clearance). Moreover, we did not evaluate different complex apo-B-containing lipo-and renal diagnosis, but not dyslipidaemia, were significant risk factors for the rate of Ccr decline to dialysis proteins, which have been shown to be a better predictor of renal disease progression [13] . Nevertheless, in CRF patients. Such findings are of potential relevance in the management of CRF patients as proteinuria we previously demonstrated that dyslipidaemia, particularly HDL cholesterol, is a significant risk factor is presently amenable to specific therapeutic interventions. It has been demonstrated that ACE inhibitors for cardiovascular events in the same cohort of patients [14] . Thus, it appears that dyslipidaemia is a better are capable of decreasing proteinuria and preserving renal function in CRF patients [29] . Correcting dyslipipredictor for cardiovascular events than for renal disease progression in such patients. daemia, however, does not appear to be an essential strategy to prevent the progression of CRF to dialysis Serum Lp(a) concentrations were not correlated with CRF progression in our study. A previous study in such patients. It remains possible that lipid-lowering treatment prescribed for cardiovascular prevention similarly failed to demonstrate a close relationship between serum Lp(a) concentrations and the rate of could help to preserve the renal function in CRF patients. progression of CRF [20] . However, in view of the skewed distribution of serum Lp(a) concentrations the may preclude a definitive conclusion.
In agreement with the results of others, proteinuria was found to be an independent risk factor for progres-References sion of CRF [12, 13, [21] [22] [23] . The fact that in multivariate analysis, baseline proteinuria, renal function and
